Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the ...
Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...
Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children and ...
Treatment with etanercept plus methotrexate has been shown to be effective in patients with rheumatoid arthritis (RA). Sulfasalazine is widely prescribed for the treatment of RA; however, it is not ...
The Assessment Report included 3 double-blind RCTs that evaluated etanercept at a dose of 25 mg or 50 mg twice a week. In total, 1,347 patients were enrolled in the RCTs. The Assessment Group deemed ...
Toxic epidermal necrolysis (TEN) is a rare, life-threatening drug reaction characterized by widespread epidermal necrosis and detachment. It results in severe morbidity, with mortality rates of up to ...
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has endorsed a new indication for the tumor necrosis factor inhibitor etanercept (Enbrel, Pfizer). On June 26, the ...
Review the side-effects of Etanercept as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
(HealthDay)—Treatment of rabbits with a partial spinal cord injury (SCI) with the intramuscularly-administered tumor necrosis factor-α (TNF-α) inhibitor etanercept is associated with improved clinical ...
(HealthDay)—Compared with placebo, transforaminal injections of etanercept provide relief from leg and back pain in patients with symptomatic lumbar disc herniation (LDH), according to research ...
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Etanercept - Biosimilar Insight, 2024" report has been added to ResearchAndMarkets.com's offering. This "Etanercept - Biosimilar Insight, 2024" report ...
The Assessment Report included 3 double-blind RCTs that evaluated etanercept at a dose of 25 mg or 50 mg twice a week. In total, 1,347 patients were enrolled in the RCTs. The Assessment Group deemed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results